Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 2, 2005, Pages 708-720

  Vilchèze, Catherine ^a   Weisbrod, Torin R ^a   Chen, Bing ^a   Kremer, Laurent ^b,e   Hazbón, Manzour H ^c   Wang, Feng ^d   Alland, David ^c   Sacchettini, James C ^d   Jacobs Jr , William R ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b INSTITUT PASTEUR DE LILLE   (France)

^c RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

^e CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ETHIONAMIDE; ISONIAZID; NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GENE; BACTERIAL GENETICS; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME ACTIVITY; GENE MUTATION; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PRIORITY JOURNAL;

ANTITUBERCULAR AGENTS; BLOTTING, WESTERN; CULTURE MEDIA; DRUG RESISTANCE, BACTERIAL; ETHIONAMIDE; GENE EXPRESSION REGULATION, BACTERIAL; ISONIAZID; MICROBIAL SENSITIVITY TESTS; MUTATION; MYCOBACTERIUM; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; NAD; NADH DEHYDROGENASE; PHENOTYPE; PLASMIDS; QUINONE REDUCTASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMATION, GENETIC;

EID: 12944255779     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.2.708-720.2005     Document Type: Article

References (57)

1. Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, K. S. Um, T. Wilson, D. Collins, G. de Lisle, and W. R. Jacobs, Jr. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science 263:227-230.
2. Basso, L. A., R. Zheng, J. M. Musser, W. R. Jacobs, Jr., and J. S. Blanchard. 1998. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 178:769-775.
3. Baulard, A. R., J. C. Betts, J. Engohang-Ndong, S. Quan, R. A. McAdam, P. J. Brennan, C. Locht, and G. S. Besra. 2000. Activation of the pro-drug ethionamide is regulated in mycobacteria. J. Biol. Chem. 275:28326-28331.
4. Bernstein, J. W., A. Lott, B. A. Steinberg, and H. L. Yale. 1952. Chemotherapy of experimental tuberculosis. Am. Rev. Tuberc. 65:357-374.
5. Calhoun, M. W., K. L. Oden, R. B. Gennis, M. J. de Mattos, and O. M. Neijssel. 1993. Energetic efficiency of Escherichia coli: effects of mutations in components of the aerobic respiratory chain. J. Bacteriol. 175:3020-3025.
6. Canetti, G. 1965. Present aspects of bacterial resistance in tuberculosis. Am. Rev. Respir. Dis. 92:687-703.
7. Canetti, G., B. Kreis, R. G. Thibier, and M. P. Le Lirzin. 1967. Current data on primary resistance in pulmonary tuberculosis in adults in France. 2d survey of the Centre d'Etudes sur la Resistance Primaire: 1965-1966. Rev. Tuberc. Pneumol. (Paris) 31:433-474.
8. +-binding proteins in mycobacterial INH resistance. Infect. Immun. 66:5099-5106.
9. Corbett, E. L., C. J. Watt, N. Walker, D. Maher, B. G. Williams, M. C. Raviglione, and C. Dye. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-1021.
10. DeBarber, A. E., K. Mdluli, M. Bosman, L. G. Bekker, and C. E. Barry III. 2000. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA 97:9677-9682.
11. Dessen, A., A. Quemard, J. S. Blanchard, W. R. Jacobs, Jr., and J. C. Sacchettini. 1995. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267:1638-1641.
12. Espinal, M. A. 2003. The global situation of MDR-TB. Tuberculosis 83:44-51.
13. Fox, H. H. 1952. The chemical approach to the control of tuberculosis. Science 116:129-134.
14. Fraaije, M. W., N. M. Kamerbeek, A. J. Heidekamp, R. Fortin, and D. B. Janssen. 2004. The prodrug activator EtaA from Mycobacterium tuberculosis is a Baeyer-Villiger monooxygenase. J. Biol. Chem. 279:3354-3360.
15. Gennis, R. B., and V. Stewart. 1996. Respiration, p. 217-261. In F. C. Neidhardt, R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger (ed.), Escherichia coli and Salmonella: cellular and molecular biology, vol. 1. ASM Press, Washington, D.C.
16. Green, J., and J. R. Guest. 1994, Regulation of transcription at the ndh promoter of Escherichia coli by FNR and novel factors. Mol. Microbiol. 12:433-444.
17. Heym, B., N. Honore, C. Truffot-Pernot, A. Banerjee, C. Schurra, W. R. Jacobs, Jr., J. D. van Embden, J. H. Grosset, and S. T. Cole. 1994. Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study. Lancet 344:293-298.
18. Hok, T. T. 1964. A comparative study of the susceptibility to ethionamide, thiosemicarbazone, and isoniazid of tubercle bacilli from patients never treated with ethionamide or thiosemicarbazone. Am. Rev. Respir. Dis. 90:468-469.
19. Jaworowski, A., G. Mayo, D. C. Shaw, H. D. Campbell, and I. G. Young. 1981. Characterization of the respiratory NADH dehydrogenase of Escherichia coli and reconstitution of NADH oxidase in ndh mutant membrane vesicles. Biochemistry 20:3621-3628.
20. Johnsson, K., and P. G. Schultz. 1994. Mechanistic studies of the oxidation of isoniazid by the catalase peroxidase from Mycobacterium tuberculosis. J. Am. Chem. Soc. 116:7425-7426.
21. Kerscher, S. J. 2000. Diversity and origin of alternative NADH:ubiquinone oxidoreductases. Biochim. Biophys. Acta 1459:274-283.
22. Kiepiela, P., K. S. Bishop, A. N. Smith, L. Roux, and D. F. York. 2000. Genomic mutations in the katG, inhA and aphC genes are useful for the prediction of isoniazid resistance in Mycobacterium tuberculosis isolates from Kwazulu Natal, South Africa. Tuberc. Lung Dis. 80:47-56.
23. Kremer, L., L. G. Dover, H. R. Morbidoni, C. Vilcheze, W. N. Maughan, A. Baulard, S. Tu, N. Honore, V. Deretic, J. C. Sacchettini, C. Locht, W. R. J. Jacobs, and G. Besra. 2003. Inhibition of InhA activity, but not KasA activity, induces formation of a KasA-containing complex in mycobacteria. J. Biol. Chem. 278:20547-20554.
24. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
25. Larsen, M. H. 2000. Some common methods in mycobacterial genetics, p. 313-320. In G. F. Hatfull and W. R. Jacobs, Jr. (ed.), Molecular genetics of mycobacteria. ASM Press, Washington, D.C.
26. Larsen, M. H., C. Vilcheze, L. Kremer, G. S. Besra, L. Parsons, M. Salfinger, L. Heifets, M. H. Hazbon, D. Alland, J. C. Sacchettini, and W. R. Jacobs, Jr. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 46:453-466.
27. Lee, A. S., A. S. Teo, and S. Y. Wong. 2001. Novel mutations in ndh in isoniazid-resistant Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 45:2157-2159.
28. Lefford, M. J. 1966. The ethionamide sensitivity of British pre-treatment strains of Mycobacterium tuberculosis. Tubercle 47:198-206.
29. Lei, B., C. J. Wei, and S. C. Tu. 2000. Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor. J. Biol. Chem. 275:2520-2526.
30. Leonardo, M. R., Y. Dailly, and D. P. Clark. 1996. Role of NAD in regulating the adhE gene of Eschenchia coli. J. Bacteriol. 178:6013-6018.
31. Madison, B. M., S. H. Siddiqi, L. Heifets, W. Gross, M. Higgins, N. Warren, A. Thompson, G. Morlock, and J. C. Ridderhof. 2004. Identification of a Mycobacterium tuberculosis strain with stable, low-level resistance to isoniazid. J. Clin. Microbiol. 42:1294-1295.
32. Matsushita, K., T. Ohnishi, and H. R. Kaback. 1987. NADH-ubiquinone oxidoreductases of the Eschenchia coli aerobic respiratory chain. Biochemistry 26:7732-7737.
33. McKie, J. H., and K. T. Douglas. 1991. Evidence for gene duplication forming similar binding folds for NAD(P)H and FAD in pyridine nucleotide-dependent flavoenzymes. FEBS Lett. 279:5-8.
34. McMurry, L. M., P. F. McDermott, and S. B. Levy. 1999. Genetic evidence that InhA of Mycobacterium smegmatis is a target for triclosan. Antimicrob. Agents Chemother. 43:711-713.
35. Middlebrook, G., and M. L. Cohn. 1953. Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. Science 118:297-299.
36. Miesel, L., T. R. Weisbrod, J. A. Marcinkeviciene, R. Bittman, and W. R. Jacobs, Jr. 1998. NADH dehydrogenase defects confer isoniazid resistance and conditional lethality in Mycobacterium smegmatis. J. Bacteriol. 180:2459-2467.
37. Molenaar, D., M. E. van der Rest, A. Drysch, and R. Yucel. 2000. Functions of the membrane-associated and cytoplasmic malate dehydrogenases in the citric acid cycle of Corynebacterium glutamicum. J. Bacteriol. 182:6884-6891.
38. Morlock, G. P., B. Metchock, D. Sikes, J. T. Crawford, and R. C. Cooksey. 2003. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 47:3799-3805.
39. Neijssel, O. M., and M. J. Teixeira de Mattos. 1994. The energetics of bacterial growth: a reassessment. Mol. Microbiol. 13:172-182.
40. Nguyen, M., A. Quemard, S. Broussy, J. Bernadou, and B. Meunier. 2002. Mn(III) pyrophosphate as an efficient tool for studying the mode of action of isoniazid on the InhA protein of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 46:2137-2144.
41. Piatek, A. S., A. Telenti, M. R. Murray, H. El-Hajj, W. R. Jacobs, Jr., F. R. Kramer, and D. Alland. 2000. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob. Agents Chemother. 44:103-110.
42. Quemard, A., J. C. Sacchettini, A. Dessen, C. Vilcheze, R. Bittman, W. R. Jacobs, Jr., and J. S. Blanchard. 1995. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34:8235-8241.
43. Ramaswamy, S. V., R. Reich, S. J. Dou, L. Jasperse, X. Pan, A. Wanger, T. Quitugua, and E. A. Graviss. 2003. Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 47:1241-1250.
44. Rawat, R., A. Whitty, and P. J. Tonge. 2003. The isoniazid-NAD adduct is a slow, tight-binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: adduct affinity and drug resistance. Proc. Natl. Acad. Sci. USA 100:13881-13886.
45. Rozwarski, D. A., G. A. Grant, D. H. Barton, W. R. Jacobs, Jr., and J. C. Sacchettini. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science 279:98-102.
46. San, K. Y., G. N. Bennett, S. J. Berrios-Rivera, R. V. Vadali, Y. T. Yang, E. Horton, F. B. Rudolph, B. Sariyar, and K. Blackwood. 2002. Metabolic engineering through cofactor manipulation and its effects on metabolic flux redistribution in Escherichia coli. Metab. Eng. 4:182-192.
47. Sonnhammer, E. L., G. von Heijne, and A. Krogh. 1998. A hidden Markov model for predicting transmembrane helices in protein sequences. Proc. Int. Conf. Intell. Syst. Mol. Biol. 6:175-182.
48. Stover, C. K., V. F. de la Cruz, T. R. Fuerst, J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull, et al. 1991. New use of BCG for recombinant vaccines. Nature 351:456-460.
49. Takayama, K., L. Wang, and H. L. David. 1972. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2:29-35.
50. Vannelli, T. A., A. Dykman, and P. R. Ortiz de Montellano. 2002. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J. Biol. Chem. 277:12824-12829.
51. Vilcheze, C., H. R. Morbidoni, T. R. Weisbrod, H. Iwamoto, M. Kuo, J. C. Sacchettini, and W. R. Jacobs, Jr. 2000. Inactivation of the inhA-encoded fatty acid synthase II (FASII) enoyl-acyl carrier protein reductase induces accumulation of the FASI end products and cell lysis of Mycobacterium smegmatis. J. Bacteriol. 182:4059-4067.
52. Wilming, M., and K. Johnsson. 1999. Spontaneous formation of the bioactive form of the tuberculosis drug isoniazid. Angew Chem. Int. Ed. 38:2588-2590.
53. World Health Organization. 2000. Anti-tuberculosis drug resistance in the world. Report no. 2: prevalence and trends. The W.H.O./IUATLD global project on anti-tuberculosis drug resistance surveillance. World Health Organization, Geneva, Switzerland.
54. Yagi, T. 1993. The bacterial energy-transducing NADH-quinone oxidoreductases. Biochim. Biophys. Acta 1141:1-17.
55. Yagi, T., T. Yano, S. Di Bernardo, and A. Matsuno-Yagi. 1998. Procaryotic complex I (NDH-1), an overview. Biochim. Biophys. Acta 1364:125-133.
56. Zhang, Y., T. Garbe, and D. Young. 1993. Transformation with katG restores isoniazid sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations. Mol. Microbiol. 8:521-524.
57. Zhang, Y., B. Heym, B. Allen, D. Young, and S. Cole. 1992. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 358:591-593.